Sermorelin vs Tesamorelin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH, retaining full biological activity at the GHRH receptor. It was FDA approved (Geref) for GH deficiency in children from 1997 until its voluntary market withdrawal in 2008 for commercial reasons - not...
Calculate Sermorelin dose →Tesamorelin is an FDA-approved synthetic GHRH analog (Egrifta) modified with trans-3-hexenoic acid to resist DPP-IV enzymatic cleavage, doubling its effective half-life. It restores pulsatile GH secretion and preferentially reduces visceral adipose tissue. Approved in 2010 for HI...
Calculate Tesamorelin dose →| Parameter | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Research | Extensively Studied | FDA Approved |
| Half-Life | ~10–20 min | ~26–38 min |
| Typical Dose | 200–500 µg | 1–2 mg |
| Frequency | Once daily (bedtime) | Once daily |
| Route | Subcutaneous | Subcutaneous |
| FDA Status | Compounding Only | Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.